Gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate; advanced renal cell carcinoma; advanced Pancreatic Neuroendocrine Tumors.
For gastrointestinal stromal tumor and
advanced renal cell carcinoma: 50mg OD on a
regime of 4 weeks on treatment followed by 2
weeks off. For advanced Pancreatic Neuroendocrine Tumors: 37.5mg OD on constinous basis
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Tyrosine kinase inhibitor
Myelosuppression associated with neutropenia, thrombocytopenia and anemia.